Evidence map›Paper›PMID 37509372›Full record

ArticleCancers2023

Using Single-Voxel Magnetic Resonance Spectroscopy Data Acquired at 1.5T to Classify Multivoxel Data at 3T: A Proof-of-Concept Study.

Gülnur Ungan, Albert Pons-Escoda, Daniel Ulinic, Carles Arús, Alfredo Vellido, Margarida Julià-Sapé

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gülnur UnganCentro de Investigación Biomédica en Red (CIBER), 28029 Madrid, Spain.
Albert Pons-EscodaGroup de Neuro-Oncologia, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Universitari de Bellvitge, 08908 Barcelona, Spain.ORCID 0000-0003-4167-8291
Daniel UlinicDepartament de Bioquímica i Biologia Molecular and Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.ORCID 0009-0006-3318-0839
Carles ArúsCentro de Investigación Biomédica en Red (CIBER), 28029 Madrid, Spain.ORCID 0000-0003-2510-2671
Alfredo VellidoCentro de Investigación Biomédica en Red (CIBER), 28029 Madrid, Spain.
Margarida Julià-SapéCentro de Investigación Biomédica en Red (CIBER), 28029 Madrid, Spain.ORCID 0000-0002-3316-9027

Funding

Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina CB06/01/0010European Union FP5-IST-1999-10310European Union FP6-2002-LIFESCIHEALTH- 503094European Union H2020-MSCA-ITN-2018-813120Generalitat de Catalunya 2018 XARDI 00016Generalitat de Catalunya 2021 XARDI 00021Proyectos de investigación en salud 2020 PI20/00064Proyectos de investigación en salud 2020 PI20/00360Spanish AEI PID2019-104551RB-I00
6 · The paper itself

Abstract

In vivo magnetic resonance spectroscopy (MRS) has two modalities, single-voxel (SV) and multivoxel (MV), in which one or more contiguous grids of SVs are acquired. PURPOSE: To test whether MV grids can be classified with models trained with SV.

methodsRetrospective study. Training dataset: Multicenter multiformat SV INTERPRET, 1.5T. Testing dataset: MV eTumour, 3T. Two classification tasks were completed: 3-class (meningioma vs. aggressive vs. normal) and 4-class (meningioma vs. low-grade glioma vs. aggressive vs. normal). Five different methods were tested for feature selection. The classification was implemented using linear discriminant analysis (LDA), random forest, and support vector machines. The evaluation was completed with balanced error rate (BER) and area under the curve (AUC) on both sets. The accuracy in class prediction was calculated by developing a solid tumor index (STI) and segmentation accuracy with the Dice score.

resultsThe best method was sequential forward feature selection combined with LDA, with AUCs = 0.95 (meningioma), 0.89 (aggressive), 0.82 (low-grade glioma), and 0.82 (normal). STI was 66% (4-class task) and 71% (3-class task) because two cases failed completely and two more had suboptimal STI as defined by us. DISCUSSION: The reasons for failure in the classification of the MV test set were related to the presence of artifacts.

Indexed as

brain tumorsdecision support systemsglioblastomamagnetic resonance spectroscopymetabolic patternnosologic imaging

Identifiers

PMID37509372
PMCPMC10377805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.